文献速递临床试验与 GCP

拔管后经鼻高流量氧疗联合无创通气与单纯经鼻高流量氧疗对拔管失败高风险患者再插管影响的随机临床试验

Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

该多中心随机临床试验在法国30个ICU纳入641例拔管失败高风险患者,比较拔管后立即给予经鼻高流量氧疗联合无创通气与单纯经鼻高流量氧疗的效果。结果显示,联合组第7天再插管率为11.8%,显著低于单纯组的18.2%(差值-6.4%,95%CI -12.0%至-0.9%;P=0.02),拔管后呼吸衰竭和ICU出院前再插管率也显著降低,但ICU死亡率无显著差异。

要点

  • 拔管后立即使用经鼻高流量氧疗联合无创通气可降低第7天再插管率。
  • 联合组第7天再插管率11.8%,单纯组18.2%,差值-6.4%(95%CI -12.0%至-0.9%;P=0.02)。
  • 两组ICU死亡率无显著差异(6% vs 9%;差值-2.4%,95%CI -6.7%至1.7%;P=0.25)。

核心结论

  • 在拔管失败高风险的机械通气患者中,拔管后立即使用经鼻高流量氧疗联合无创通气较单纯经鼻高流量氧疗显著降低再插管风险。

研究设计与样本

  • 多中心随机临床试验,2017年4月至2018年1月在法国30个ICU纳入641例拔管失败高风险患者(年龄>65岁或伴有基础心脏或呼吸系统疾病),随访至2018年4月。
  • 患者拔管后随机分为单纯经鼻高流量氧疗组(n=306)和经鼻高流量氧疗交替无创通气组(n=342)。

主要发现

  • 第7天再插管率:经鼻高流量氧疗联合无创通气组11.8%(95%CI 8.4%-15.2%;40/339) vs 单纯经鼻高流量氧疗组18.2%(95%CI 13.9%-22.6%;55/302),差值-6.4%(95%CI -12.0%至-0.9%;P=0.02)。
  • 第7天拔管后呼吸衰竭比例:联合组21% vs 单纯组29%,差值-8.7%(95%CI -15.2%至-1.8%;P=0.01)。
  • ICU出院前再插管率:联合组12% vs 单纯组20%,差值-7.4%(95%CI -13.2%至-1.8%;P=0.009)。
  • ICU死亡率:联合组6% vs 单纯组9%,差值-2.4%(95%CI -6.7%至1.7%;P=0.25),无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: High-flow nasal oxygen may prevent postextubation respiratory failure in the intensive care unit (ICU). The combination of high-flow nasal oxygen with noninvasive ventilation (NIV) may be an optimal strategy of ventilation to avoid reintubation. OBJECTIVE: To determine whether high-flow nasal oxygen with prophylactic NIV applied immediately after extubation could reduce the rate of reintubation, compared with high-flow nasal oxygen alone, in patients at high risk of extubation failure in the ICU. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial conducted from April 2017 to January 2018 among 641 patients at high risk of extubation failure (ie, older than 65 years or with an underlying cardiac or respiratory disease) at 30 ICUs in France; follow-up was until April 2018. INTERVENTIONS: Patients were randomly assigned to high-flow nasal oxygen alone (n = 306) or high-flow nasal oxygen alternating with NIV (n = 342) immediately after extubation. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients reintubated at day 7; secondary outcomes included postextubation respiratory failure at day 7, reintubation rates up until ICU discharge, and ICU mortality. RESULTS: Among 648 patients who were randomized (mean [SD] age, 70 [10] years; 219 women [34%]), 641 patients completed the trial. The reintubation rate at day 7 was 11.8% (95% CI, 8.4%-15.2%) (40/339) with high-flow nasal oxygen and NIV and 18.2% (95% CI, 13.9%-22.6%) (55/302) with high-flow nasal oxygen alone (difference, -6.4% [95% CI, -12.0% to -0.9%]; P = .02). Among the 11 prespecified secondary outcomes, 6 showed no significant difference. The proportion of patients with postextubation respiratory failure at day 7 (21% vs 29%; difference, -8.7% [95% CI, -15.2% to -1.8%]; P = .01) and reintubation rates up until ICU discharge (12% vs 20%, difference -7.4% [95% CI, -13.2% to -1.8%]; P = .009) were significantly lower with high-flow nasal oxygen and NIV than with high-flow nasal oxygen alone. ICU mortality rates were not significantly different: 6% with high-flow nasal oxygen and NIV and 9% with high-flow nasal oxygen alone (difference, -2.4% [95% CI, -6.7% to 1.7%]; P = .25). CONCLUSIONS AND RELEVANCE: In mechanically ventilated patients at high risk of extubation failure, the use of high-flow nasal oxygen with NIV immediately after extubation significantly decreased the risk of reintubation compared with high-flow nasal oxygen alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03121482.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Thille AW, Muller G, Gacouin A, et al. Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial. JAMA. 2019. PMID: 31577036. doi:10.1001/jama.2019.14901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。